Trudhesa® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021
Planned initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in 2Q 2022
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Trudhesa® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021
Planned initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in 2Q 2022
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| IMPL | 0.0400 | -0.0150 | -27.27% |
| Impel Pharmaceuticals Inc | |||